Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Therapeutics symbols : Onct save search
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-07 (Crawled : 21:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: -0.22%
H: 3.9%
C: 3.9%
business year update therapeutics financial results
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-06 (Crawled : 22:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: -3.64%
H: 1.02%
C: 1.02%
conference life sciences therapeutics
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - February 1, 2024
Published: 2024-02-01 (Crawled : 22:00) - biospace.com/
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: -2.66%
H: 6.01%
C: -0.53%
award nasdaq therapeutics
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-01 (Crawled : 14:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: -2.66%
H: 6.01%
C: -0.53%
award nasdaq therapeutics
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Published: 2024-01-08 (Crawled : 14:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: 4.93%
H: 3.89%
C: 0.14%
onct-534 cancer treatment therapeutics study
Oncternal Therapeutics Announces Reverse Stock Split
Published: 2024-01-04 (Crawled : 14:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: -3.25%
H: 8.33%
C: -21.96%
therapeutics
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-02 (Crawled : 14:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: 0.43%
H: 6.28%
C: 2.88%
award nasdaq therapeutics
Oncternal Therapeutics Updates the Status of its Phase 1/2 Study of ONCT-808, a ROR1-Targeting Autologous CAR T, in Patients with Relapsed or Refractory Aggressive B-cell Lymphoma
Published: 2023-12-26 (Crawled : 14:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: -16.39%
H: 19.98%
C: 18.2%
onct-808 therapeutics study
Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results
Published: 2023-11-02 (Crawled : 20:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: 2.78%
H: 8.82%
C: 5.88%
report business update therapeutics financial results
Oncternal Therapeutics Announces FDA Granted Fast Track Designation for ONCT-534 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Published: 2023-10-26 (Crawled : 13:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: 12.87%
H: 0.0%
C: -8.86%
onct-534 fda granted cancer treatment designation therapeutics
Oncternal Therapeutics Adds Matthew Smith, M.D., Ph.D. to its Prostate Cancer Scientific Advisory Board
Published: 2023-10-25 (Crawled : 13:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: -1.59%
H: 10.94%
C: 0.03%
cancer therapeutics
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer
Published: 2023-10-05 (Crawled : 20:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: 0.0%
H: 6.56%
C: 0.33%
onct-534 cancer therapeutics study
Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board
Published: 2023-09-07 (Crawled : 13:00) - globenewswire.com
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 1.03%
H: 0.0%
C: 0.0%
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: 2.53%
H: 1.68%
C: -0.13%
cancer therapeutics
Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results
Published: 2023-08-03 (Crawled : 20:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: 2.29%
H: 0.26%
C: -8.74%
report business update therapeutics financial results
Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer
Published: 2023-08-03 (Crawled : 20:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: 2.29%
H: 0.26%
C: -8.74%
onct-534 fda cancer treatment therapeutics study
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-06-30 (Crawled : 20:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
| Email alert
Add to watchlist
award nasdaq therapeutics
Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma
Published: 2023-06-06 (Crawled : 20:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: -1.15%
H: 7.27%
C: 2.93%
onct-808 therapeutics study
Oncternal Therapeutics to Participate at the 2023 Jefferies Healthcare Conference
Published: 2023-05-31 (Crawled : 21:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: -1.72%
H: 6.53%
C: 6.53%
conference therapeutics
Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results
Published: 2023-05-04 (Crawled : 20:00) - globenewswire.com
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: 7.97%
H: 0.0%
C: -3.28%
business update therapeutics financial results
Oncternal Therapeutics to Provide Business Update and Report First Quarter 2023 Financial Results
Published: 2023-04-27 (Crawled : 22:00) - biospace.com/
ONCT | $8.98 5.03% 4.79% 960
|
Health Technology
|
| O: 2.47%
H: 4.06%
C: 4.06%
report business update therapeutics financial results
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News M | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.